Literature DB >> 8943482

Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy.

E Ranieri1, L Gesualdo, F Petrarulo, F P Schena.   

Abstract

Interleukin 6 (IL-6) is produced by human mesangial and tubular cells, and its urinary levels has been proposed as a marker of mesangial proliferation and tubulointerstitial damage. Epidermal growth factor (EGF) is expressed within the Henle's loop and the distal tubule and has been shown to accelerate recovery from renal injury. In the present study we have defined renal gene and protein expression of IL-6 and EGF in 10 normal, 10 nonproliferative glomerulonephritis (NPGN) and 30 IgA nephropathy (IgAN) human kidneys by RT-PCR, in situ hybridization and immunohistochemical techniques. Moreover, urinary IL-6 and EGF levels were measured in 41 patients with IgAN and in 20 normal subjects (N). In normal kidneys, EGF was localized in Henle's loop and distal convoluted tubule whereas IL-6 was mainly located in the proximal tubule and, less, within the glomerulus. In IgAN patients, EGF was decreased whereas IL-6 expression was upregulated. These modifications paralleled the degree of tubulointerstitial damage. Moreover, IgAN patients as a whole exhibited a reduction of EGF and an increase of IL-6 urinary concentration (EGF values: N, 12.96 +/- 1.15; IgAN Grades 1-2, 20.05 +/- 2.64; Grades 3-4 7.60 +/- 1.70: Grade 5, 3.14 +/- 0.71, ng/mg urinary creatinine. IL-6 values: N, 2.04 +/- 0.51; IgAN Grades 1-2, 3.26 +/- 0.38; Grades 3-4, 5.67 +/- 0.92; Grade 5, 27.20 +/- 9.70 pg/mg urinary creatinine), that correlated with the degree of histological lesions, the presence of hypertension and serum creatinine level. Interestingly, patients with the highest urinary IL-6/EGF ratio showed a worse evolution in a three year follow-up. In conclusion, our data show that: (1) renal IL-6 and EGF expression are strictly correlated to the degree of tubulointerstitial damage; and (2) urinary IL-6/EGF ratio might be a valuable prognostic marker for the progression of the renal damage in IgAN.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943482     DOI: 10.1038/ki.1996.521

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  20 in total

Review 1.  Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease.

Authors:  Helena M Kok; Lucas L Falke; Roel Goldschmeding; Tri Q Nguyen
Journal:  Nat Rev Nephrol       Date:  2014-10-14       Impact factor: 28.314

Review 2.  Treatment of IgA nephropathy and Henoch-Schönlein nephritis.

Authors:  Jürgen Floege; John Feehally
Journal:  Nat Rev Nephrol       Date:  2013-04-02       Impact factor: 28.314

3.  Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.

Authors:  Natalia Nowak; Jan Skupien; Adam M Smiles; Masayuki Yamanouchi; Monika A Niewczas; Andrzej T Galecki; Kevin L Duffin; Matthew D Breyer; Nick Pullen; Joseph V Bonventre; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2018-02-02       Impact factor: 10.612

4.  Association of urinary laminin G-like 3 and free K light chains with disease activity and histological injury in IgA nephropathy.

Authors:  Maria Teresa Rocchetti; Massimo Papale; Anna Maria d'Apollo; Ida Valentina Suriano; Anna Maria Di Palma; Grazia Vocino; Eustacchio Montemurno; Leonarda Varraso; Giuseppe Grandaliano; Salvatore Di Paolo; Loreto Gesualdo
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 8.237

5.  The profile of gene expression and role of nuclear factor kappa B on glomerular injury in rats with Thy-1 nephritis.

Authors:  H Wang; X M Jiang; J H Xu; J Xu; J X Tong; Y W Wang
Journal:  Clin Exp Immunol       Date:  2008-04-16       Impact factor: 4.330

Review 6.  Markers for the progression of IgA nephropathy.

Authors:  Dita Maixnerova; Colin Reily; Qi Bian; Michaela Neprasova; Jan Novak; Vladimir Tesar
Journal:  J Nephrol       Date:  2016-05-03       Impact factor: 3.902

7.  Non-invasive markers of ureteropelvic junction obstruction.

Authors:  Stephane Decramer; Jean-Loup Bascands; Joost P Schanstra
Journal:  World J Urol       Date:  2007-08-14       Impact factor: 4.226

8.  Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker.

Authors:  Wenjun Ju; Viji Nair; Shahaan Smith; Li Zhu; Kerby Shedden; Peter X K Song; Laura H Mariani; Felix H Eichinger; Celine C Berthier; Ann Randolph; Jennifer Yi-Chun Lai; Yan Zhou; Jennifer J Hawkins; Markus Bitzer; Matthew G Sampson; Martina Thier; Corinne Solier; Gonzalo C Duran-Pacheco; Guillemette Duchateau-Nguyen; Laurent Essioux; Brigitte Schott; Ivan Formentini; Maria C Magnone; Maria Bobadilla; Clemens D Cohen; Serena M Bagnasco; Laura Barisoni; Jicheng Lv; Hong Zhang; Hai-Yan Wang; Frank C Brosius; Crystal A Gadegbeku; Matthias Kretzler
Journal:  Sci Transl Med       Date:  2015-12-02       Impact factor: 17.956

9.  MicroRNA-let-7a promotes E2F-mediated cell proliferation and NFκB activation in vitro.

Authors:  Cristen B Chafin; Nicole L Regna; David L Caudell; Christopher M Reilly
Journal:  Cell Mol Immunol       Date:  2013-11-18       Impact factor: 11.530

10.  TREM-1 Contributes to Inflammation in IgA Nephropathy.

Authors:  Yan-Feng Zhao; Li Zhu; Li-Jun Liu; Su-Fang Shi; Ji-Cheng Lv; Hong Zhang
Journal:  Kidney Dis (Basel)       Date:  2018-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.